Clinical Trial 3145

Trinity, Fl 34655


Study Summary:

A phase III, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNT-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Chrohn's disease.


Qualified Participants Must:

• Have no previous treatment w/ anti TNIF agents
• Have diagnosis 6 months or greater


Qualified Participants May Receive:

All study related procedures including labs and Diagnostic Testing are at no cost to you.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.